Citizens Financial Group Inc. RI increased its stake in McKesson Co. (NYSE:MCK - Free Report) by 85.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,233 shares of the company's stock after buying an additional 1,954 shares during the period. Citizens Financial Group Inc. RI's holdings in McKesson were worth $2,412,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. MidAtlantic Capital Management Inc. bought a new position in shares of McKesson in the 3rd quarter worth approximately $29,000. RPg Family Wealth Advisory LLC purchased a new stake in McKesson in the third quarter worth $31,000. Synergy Asset Management LLC bought a new position in McKesson in the fourth quarter worth $32,000. Crews Bank & Trust purchased a new position in McKesson during the fourth quarter valued at $33,000. Finally, Creative Capital Management Investments LLC bought a new stake in shares of McKesson during the 4th quarter valued at $44,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at McKesson
In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the completion of the sale, the chief executive officer now directly owns 60,664 shares of the company's stock, valued at approximately $36,276,465.36. This represents a 12.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Leann B. Smith sold 188 shares of the stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the transaction, the executive vice president now owns 1,051 shares in the company, valued at $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,689 shares of company stock valued at $11,187,351. 0.11% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
MCK has been the subject of several research reports. StockNews.com lowered shares of McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Wells Fargo & Company lifted their target price on shares of McKesson from $535.00 to $641.00 and gave the company an "equal weight" rating in a report on Friday, December 13th. Morgan Stanley boosted their price target on McKesson from $612.00 to $642.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 17th. Citigroup reduced their price objective on McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Finally, Evercore ISI boosted their target price on McKesson from $650.00 to $675.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $645.79.
Read Our Latest Stock Report on MCK
McKesson Stock Down 0.8 %
Shares of NYSE MCK opened at $653.54 on Wednesday. The firm's 50-day moving average price is $604.12 and its 200-day moving average price is $568.96. McKesson Co. has a 52-week low of $464.42 and a 52-week high of $663.61. The company has a market cap of $81.91 billion, a PE ratio of 29.92, a PEG ratio of 1.29 and a beta of 0.52.
McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. As a group, equities research analysts anticipate that McKesson Co. will post 32.77 EPS for the current fiscal year.
McKesson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Monday, March 3rd. McKesson's dividend payout ratio (DPR) is presently 13.00%.
McKesson Company Profile
(
Free Report)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.